CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction Atherosclerotic plaque with ultrasonic attenuation affects coronary reflow and infarct size in patients with acute coronary syndrome: an intravascular ultrasound study Primary Prevention of Heart Failure in Women Myocardial bridging: contemporary understanding of pathophysiology with implications for diagnostic and therapeutic strategies Timing of Intervention in Aortic Stenosis Sex- and Race-Related Differences in Characteristics and Outcomes of Hospitalizations for Heart Failure With Preserved Ejection Fraction Mechanical circulatory support devices for acute right ventricular failure Burden of Cardiovascular Diseases in China, 1990-2016: Findings From the 2016 Global Burden of Disease Study In-stent neoatherosclerosis: a final common pathway of late stent failure Guideline‐Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient‐Pooled Analysis From the KorHF and KorAHF Registries

Review Article2020 May 28.

JOURNAL:Heart Fail Rev. Article Link

The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus

D Farmakis, C Chrysohoou, G Giamouzis et al. Keywords: AF; direct oral anticoagulants; HF; non-vitamin k antagonist oral anticoagulants; rate control; rhythm control

ABSTRACT

Heart failure (HF) and atrial fibrillation (AF) often coexist, being closely interrelated as the one increases the prevalence and incidence and worsens the prognosis of the other. Their frequent coexistence raises several challenges, including under-diagnosis of HF with preserved ejection fraction in AF and of AF in HF, characterization and diagnosis of atrial cardiomyopathy, target and impact of rate control therapy on outcomes, optimal rhythm control strategy in the era of catheter ablation, HF-related thromboembolic risk and management of anticoagulation in patients with comorbidities, such as chronic kidney disease or transient renal function worsening, coronary artery disease or acute coronary syndromes, valvular or structural heart disease interventions and cancer. In the present document, derived by an expert panel meeting, we sought to focus on the above challenging issues, outlining the existing evidence and identifying gaps in knowledge that need to be addressed.